Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2018

View Archived Issues

Otsuka awarded grant to advance OPC-167832/delamanid combination for tuberculosis

First Wave Bio cleared to begin clinical testing of lead product candidate

AbbVie presents key events from fourth quarter 2017

BiomX licenses bacterial targets for IBD

Rexgenero receives ATMP certificate from EMA for REX-001

EMA committee recommends approval of use of Ameluz with daylight PDT

Shire acquires license to AB Biosciences' PRIM program

Aravive Biologics and WuXi Biologics to expand collaboration following IND filing for AVB-S6-500

FDA places U.S. studies of BPX-501 on clinical hold

EMA committee recommends approval of biosimilar insulin glargine Semglee

Eisai and Boston University enter Alzheimer's research collaboration

Interim data from phase I/II trial of LiPlaCis in heavily pretreated breast cancer

Versican biomarker shown to be prognostic in patients with pancreatic neuroendocrine tumors

FDA gives orphan drug status to Dauntless Pharmaceuticals' DP-1038 for acromegaly

Artelo Biosciences to evaluate anticancer potential of drug from NEOMED Institute

Corbus Pharmaceuticals receives award to support phase IIb study of lenabasum

Celgene updates milestones of fourth quarter 2017

suPAR is a novel prognostic marker for metastatic CRC patients undergoing resection

Roche patents compounds for treating HBV infection

Chiesi Farmaceutici discloses new compounds for asthma

Bayer identifies new muscarinic M2 receptor PAMs

InnoCare Pharma divulges novel FGFR inhibitors for cancer

European approval of Prevymis triggers milestone payment to AiCuris

Kancera discovers ROR1 inhibitors

BridgeBio establishes QED Therapeutics to drive development of newly licensed infigratinib

Phase III trial of sublingual apomorphine meets endpoints in patients with Parkinson's disease

Inoperable HCC patients on tivozanib show durable tumor responses

Sanofi seeks EMA review of fexinidazole for sleeping sickness

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...